Skip to content Skip to footer

News

Latest news from CHV and our portfolio companies 

Featured News

AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management systems, announced today that it has entered into a financing of up to $75 million. The…

Insights & Impacts: The latest from CHV

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health

Seasoned Medical Device Executive, James Reinstein, Appointed as Chief Executive Officer Conformal Medical, Inc., a

– Grant Supports Continued Clinical Development of the Company’s PTM-101 Product and its Potential for

BEDFORD, Mass., – Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral

Study to support U.S. FDA approval of the novel CLAASâ implant for left atrial appendage

– Patent Validates Novelty and Breadth of Proprietary Sagittari™ Treatment Platform and Expands Potential for

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health

The brain (put way too simply) is a complicated organ that remains hard to fully

Project focused on reducing maternal and neonatal mortality and morbidity by mitigating risks associated with

AtaCor Medical, Inc. (“AtaCor”) announced today that it will present initial findings from its first-in-human

Interested in learning more?